![]() Read the full story by clicking on this headline.. |
Researchers have isolated for the first time a free-floating form of amyloid beta that appears to be a key driver of Alzheimer's disease. Further, they argue that a newly approved Alzheimer's drug - lecanemab (Leqembi) - directly targets these small, complex chains of... |
0 Comments
Leave a Reply. |
NewsMaxA conservative American news and opinion website founded by Christopher Ruddy in 1998 & operated by Newsmax Media. Archives
June 2023
Categories |